Ovation Science Licensee Launches Innovative Transdermal Cannabis Products in Pennsylvania
Ovation Science announces the launch of its patented transdermal cannabis products in Pennsylvania through licensee PA Options for Wellness. This marks Ovation's second US licensee, targeting a market with over 850,000 registered patients and caregivers across 170+ dispensaries. PA Options, operating six dispensaries under Vytal Options brand with 32,000 registered medical patients, will distribute Ovation's products under the 'Mood' brand.
The company's formulations utilize Invisicare® technology, showing 10 times greater CBD release through the skin compared to other tested products. Ovation is expanding its US presence, with ongoing operations in Nevada through Planet 13 and planned entry into Missouri via MidWest Roots in January 2025. The company has terminated its licensing agreement with Stash House Distribution for Oklahoma, New Mexico, and Mississippi.
Ovation Science annuncia il lancio dei suoi prodotti a base di cannabis transdermici brevettati in Pennsylvania tramite il licenziatario PA Options for Wellness. Questo segna il secondo licenziatario di Ovation negli Stati Uniti, puntando a un mercato con oltre 850.000 pazienti e caregiver registrati in più di 170 dispensari. PA Options, che gestisce sei dispensari sotto il marchio Vytal Options con 32.000 pazienti medici registrati, distribuirà i prodotti di Ovation sotto il marchio 'Mood'.
Le formulazioni della società utilizzano la tecnologia Invisicare®, mostrando un rilascio di CBD 10 volte maggiore attraverso la pelle rispetto ad altri prodotti testati. Ovation sta espandendo la sua presenza negli Stati Uniti, con operazioni in corso in Nevada tramite Planet 13 e un ingresso pianificato nel Missouri tramite MidWest Roots a gennaio 2025. La società ha terminato il suo accordo di licenza con Stash House Distribution per Oklahoma, New Mexico e Mississippi.
Ovation Science anuncia el lanzamiento de sus productos de cannabis transdérmicos patentados en Pensilvania a través del licenciatario PA Options for Wellness. Este es el segundo licenciatario de Ovation en EE. UU., apuntando a un mercado con más de 850,000 pacientes y cuidadores registrados en más de 170 dispensarios. PA Options, que opera seis dispensarios bajo la marca Vytal Options con 32,000 pacientes médicos registrados, distribuirá los productos de Ovation bajo la marca 'Mood'.
Las formulaciones de la compañía utilizan la tecnología Invisicare®, mostrando un 10 veces mayor liberación de CBD a través de la piel en comparación con otros productos probados. Ovation está expandiendo su presencia en EE. UU., con operaciones en curso en Nevada a través de Planet 13 y una entrada planificada en Missouri a través de MidWest Roots en enero de 2025. La compañía ha terminado su acuerdo de licencia con Stash House Distribution para Oklahoma, Nuevo México y Mississippi.
오베이션 사이언스는 라이센스 파트너인 PA Options for Wellness를 통해 펜실베이니아에서 자사의 특허받은 경피 대마초 제품을 출시한다고 발표했습니다. 이는 오베이션의 두 번째 미국 라이센스 파트너로, 170개 이상의 약국에서 85만 명 이상의 등록 환자와 보호자가 있는 시장을 타겟으로 합니다. Vytal Options 브랜드로 6개의 약국을 운영하는 PA Options는 32,000명의 등록된 의료 환자를 보유하고 있으며, 오베이션의 제품을 'Mood' 브랜드로 유통할 것입니다.
회사의 포뮬러는 Invisicare® 기술를 활용하여, 다른 테스트된 제품에 비해 피부를 통한 CBD 방출이 10배 더 크다는 것을 보여줍니다. 오베이션은 미국 내 존재감을 확장하고 있으며, 현재 네바다에서 Planet 13을 통해 운영 중이며, 2025년 1월 미주리로의 진입을 계획하고 있습니다. 이 회사는 오클라호마, 뉴멕시코, 미시시피를 위한 Stash House Distribution과의 라이센스 계약을 종료했습니다.
Ovation Science annonce le lancement de ses produits de cannabis transdermiques brevetés en Pennsylvanie via le licencié PA Options for Wellness. Cela marque le deuxième licencié d'Ovation aux États-Unis, ciblant un marché de plus de 850 000 patients et aidants enregistrés dans plus de 170 dispensaires. PA Options, qui gère six dispensaires sous la marque Vytal Options avec 32 000 patients médicaux enregistrés, distribuera les produits d'Ovation sous la marque 'Mood'.
Les formulations de l'entreprise utilisent la technologie Invisicare®, montrant une libération de CBD 10 fois supérieure à travers la peau par rapport à d'autres produits testés. Ovation étend sa présence aux États-Unis, avec des opérations en cours au Nevada via Planet 13 et une entrée prévue dans le Missouri via MidWest Roots en janvier 2025. L'entreprise a mis fin à son accord de licence avec Stash House Distribution pour l'Oklahoma, le Nouveau-Mexique et le Mississippi.
Ovation Science kündigt die Einführung seiner patentierten transdermalen Cannabisprodukte in Pennsylvania durch den Lizenznehmer PA Options for Wellness an. Dies markiert den zweiten Lizenznehmer von Ovation in den USA und richtet sich an einen Markt mit über 850.000 registrierten Patienten und Pflegekräften in mehr als 170 Apotheken. PA Options, das sechs Apotheken unter der Marke Vytal Options mit 32.000 registrierten medizinischen Patienten betreibt, wird die Produkte von Ovation unter der Marke 'Mood' vertreiben.
Die Formulierungen des Unternehmens nutzen die Invisicare®-Technologie, die eine 10-mal höhere CBD-Freisetzung durch die Haut im Vergleich zu anderen getesteten Produkten zeigt. Ovation expandiert seine Präsenz in den USA mit laufenden Betrieben in Nevada über Planet 13 und einem geplanten Eintritt in Missouri über MidWest Roots im Januar 2025. Das Unternehmen hat seine Lizenzvereinbarung mit Stash House Distribution für Oklahoma, New Mexico und Mississippi beendet.
- Entry into Pennsylvania's large medical cannabis market with 850,000+ registered patients
- Partnership with established distributor operating six dispensaries and 32,000 registered patients
- Product demonstrates 10x greater CBD release compared to competitors
- Planned market expansion into Missouri in January 2025
- Termination of licensing agreement for Oklahoma, New Mexico, and Mississippi markets
VANCOUVER, BC / ACCESSWIRE / December 4, 2024 / (CSE:OVAT)(OTC PINK:OVATF) - Ovation Science Inc. ("Ovation" or the "Company"), with its patented topical and transdermal cannabis products powered by its proprietary skin delivery technology Invisicare®, announces the official launch of its products in Pennsylvania through its licensee: PA Options for Wellness Inc. ("PA Options").
The launch marks Ovation's second licensee in the USA and is part of the Company's on-going strategy to seek leading cannabis companies as licensees, state-by-state across the US. Pennsylvania's medical cannabis market boasts over 850,000 registered patients and caregivers, with more than 170 dispensaries throughout the state. PA Options, founded in 2014, operates six dispensaries under the Vytal Options brand and has over 32,000 registered medical patients. The Ovation Science products will be launched through-out Pennsylvania under the brand name "Mood".
PA Options operates a 65,000-square-foot, state-of-the-art cannabis grow/processing and production facility. The company collaborates with Penn State University College of Medicine on Medical Cannabis Research and with Penn State University Harrisburg on research exploring the medicinal properties of hemp and flax.
Terry Howlett, CEO of Ovation Science, stated, "We are excited about collaborating with PA Options as both companies are focused on offering the best, most effective products to patients. Our expansion with PA Options will establish our products in a market that really needs our science-based solutions. Their impressive production facility and extensive distribution network will ensure our products resonate with dispensaries and patients across the state. By collaborating with PA Options, we're bringing this innovative approach directly to patients who need advanced, research-backed medical cannabis solutions."
Tom Trite, CEO of PA Options, stated: "Our mission has always been about more than just selling medical cannabis - it's about improving patient outcomes and quality of life. Ovation's scientifically developed products align perfectly with our commitment to transforming patient care. Their Invisicare® technology represents a quantum leap in transdermal cannabinoid delivery, offering our patients a potentially more effective, targeted approach to managing their health conditions. We're not just adding a new product line; we're introducing a medical cannabis treatment that could significantly improve how patients experience relief."
Unlike traditional cannabis products, Ovation's innovative formulations leverage advanced pharmaceutical-grade drug delivery technology that dramatically enhances cannabinoid absorption. and enables substantially more CBD, THC, and other cannabinoids to be delivered through the skin. Studies show the company's products have a 10 times greater release of CBD through the skin compared to other tested products. The products can be used for both topical skin issues and transdermal absorption into the bloodstream.
Ovation continues to expand its U.S. growth strategy with notable developments in multiple states. The Company reports ongoing success in Nevada through its licensee Planet 13 with its Medizin product line, demonstrating a strong market presence in the state. Further expanding its footprint, the Company is preparing to enter the Missouri market. This expansion, through its licensee MidWest Roots, is anticipated to occur in January 2025. Additionally, the Company announces the termination of its previously disclosed licensing agreement with Stash House Distribution for Oklahoma, New Mexico, and Mississippi, allowing for new potential licensees to enter these states.
About PA Options for Wellness, Inc.
PA Options for Wellness was founded with research in mind and a focus on patient outcomes and quality of life. Its mission is to combine plant science and medicine to bring top-quality, innovative products to the medical market and transform the lives of their patients while adhering to strict ethical standards. The company operates a 65,000 square foot, state-of-the-art cannabis grow/processing and production facility and six patient-centric cannabis dispensaries throughout Pennsylvania. The company also collaborates with medical leaders and universities in the state to advance patient care and research.
About Ovation Science Inc.
Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands; ARLO CBD Beauty and InVibe® MD ("wellness" line); all powered by its patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science teams have created a unique pipeline of over thirty proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.
Stock symbols: CSE:OVAT and OVATF in the USA on OTC Markets.
Websites: CORPORATE: www.ovationscience.com
WELLNESS: www.invibemd.com BEAUTY: www.arlocbdbeauty.com
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the states cited, continued sales in dispensaries or in retail markets or expansion to other states. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
CORPORATE INQUIRIES:
Doreen McMorran: info@ovationscience.com PH: 604-982-5700
SOURCE: Ovation Science Inc.
View the original press release on accesswire.com
FAQ
When will Ovation Science (OVATF) launch its cannabis products in Pennsylvania?
How many dispensaries will carry Ovation Science (OVATF) products in Pennsylvania?
What is the market size for Ovation Science (OVATF) products in Pennsylvania?
When will Ovation Science (OVATF) enter the Missouri market?
